9 results
8-K
EX-99.1
CRGX
CARGO Therapeutics Inc
14 May 24
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:09pm
equivalents and marketable securities of $375.9 million, providing expected cash runway into 2026.
Research and Development (R&D) Expenses: R&D expenses
DEF 14A
CRGX
CARGO Therapeutics Inc
24 Apr 24
Definitive proxy
4:27pm
. Radhakrishnan held R&D finance roles of increasing responsibility at Elan Pharmaceuticals, CV Therapeutics and the University of California, San
8-K
EX-99.1
CRGX
CARGO Therapeutics Inc
21 Mar 24
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:10pm
it expects will fund operations through 2025.
Research and development (R&D) expenses were $27.1 million for the fourth quarter of 2023, which includes … $0.7 million of non-cash stock-based compensation expense. For 2023, R&D expenses were $75.8 million, which includes $1.3 million of non-cash stock
8-K
EX-99.1
CRGX
CARGO Therapeutics Inc
13 Dec 23
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
5:22pm
and development (R&D) expenses were $22.2 million for the quarter ended September 30, 2023, compared to $8.5 million for the same period in 2022
424B4
CRGX
CARGO Therapeutics Inc
13 Nov 23
Prospectus supplement with pricing info
4:31pm
Financial Officer for the Genentech Patient Foundation. Before Genentech, Mr. Radhakrishnan held R&D finance roles of increasing responsibility
S-1
1pzeg20ml0sk7mkyd
20 Oct 23
IPO registration
4:07pm
DRS/A
7n4fp0vs8qx1vro8
4 Oct 23
Draft registration statement (amended)
12:00am
DRS
3plaztwd10ljfe8hh
1 Sep 23
Draft registration statement
12:00am
- Prev
- 1
- Next